CBT vs. CPRX
CBT (Cabot Corporation) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. CBT operates in Specialty Chemicals (Basic Materials), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, CBT returned 9.16%/yr vs 48.23%/yr for CPRX. At a 0.19 correlation, their price movements are largely independent.
Performance
CBT vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
The year-to-date returns for both investments are quite close, with CBT having a 33.22% return and CPRX slightly higher at 33.98%. Over the past 10 years, CBT has underperformed CPRX with an annualized return of 9.16%, while CPRX has yielded a comparatively higher 48.23% annualized return.
CBT
- 1D
- 0.67%
- 1M
- 13.50%
- YTD
- 33.22%
- 6M
- 38.07%
- 1Y
- 20.78%
- 3Y*
- 7.58%
- 5Y*
- 8.61%
- 10Y*
- 9.16%
CPRX
- 1D
- 0.00%
- 1M
- 8.80%
- YTD
- 33.98%
- 6M
- 38.24%
- 1Y
- 25.58%
- 3Y*
- 39.37%
- 5Y*
- 41.56%
- 10Y*
- 48.23%
CBT vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CBT Cabot Corporation | 33.22% | -25.68% | 11.25% | 27.63% | 21.38% | 28.40% | -2.16% | 14.25% | -28.70% | 24.65% |
CPRX Catalyst Pharmaceuticals, Inc. | 33.98% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between CBT and CPRX is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Nov 9, 2006 | 0.19 |
The correlation between CBT and CPRX shifts across timeframes, from 0.19 (all time) to 0.31 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
CBT:
$5.83
CPRX:
$1.74
CBT:
14.98
CPRX:
17.97
CBT:
0.81
CPRX:
0.32
CBT:
1.29
CPRX:
6.66
CBT:
$3.61B
CPRX:
$596.96M
CBT:
$916.00M
CPRX:
$378.23M
CBT:
$773.00M
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CBT vs. CPRX — Risk / Return Rank
CBT
CPRX
CBT vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cabot Corporation (CBT) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CBT | CPRX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.66 | 0.76 | -0.11 |
Sortino ratioReturn per unit of downside risk | 1.23 | 1.25 | -0.02 |
Omega ratioGain probability vs. loss probability | 1.14 | 1.16 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 0.68 | 0.93 | -0.24 |
Martin ratioReturn relative to average drawdown | 1.64 | 1.69 | -0.05 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CBT | CPRX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.66 | 0.76 | -0.11 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.26 | 0.87 | -0.62 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.26 | 0.80 | -0.54 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.09 | +0.13 |
Drawdowns
CBT vs. CPRX - Drawdown Comparison
The maximum CBT drawdown since its inception was -82.87%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for CBT and CPRX.
Loading charts...
Drawdown Indicators
| CBT | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.87% | -94.25% | +11.38% |
Max Drawdown (1Y)Largest decline over 1 year | -28.82% | -27.29% | -1.53% |
Max Drawdown (3Y)Largest decline over 3 years | -48.78% | -27.29% | -21.49% |
Max Drawdown (5Y)Largest decline over 5 years | -48.78% | -45.37% | -3.41% |
Max Drawdown (10Y)Largest decline over 10 years | -67.20% | -64.87% | -2.33% |
Current DrawdownCurrent decline from peak | -22.42% | -0.19% | -22.23% |
Average DrawdownAverage peak-to-trough decline | -20.82% | -52.06% | +31.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.03% | 14.95% | -2.92% |
Volatility
CBT vs. CPRX - Volatility Comparison
Cabot Corporation (CBT) has a higher volatility of 11.97% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 6.81%. This indicates that CBT's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CBT | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.97% | 6.81% | +5.16% |
Volatility (6M)Calculated over the trailing 6-month period | 22.21% | 23.82% | -1.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.89% | 33.60% | -1.71% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.54% | 47.86% | -14.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.33% | 60.62% | -25.29% |
Dividends
CBT vs. CPRX - Dividend Comparison
CBT's dividend yield for the trailing twelve months is around 2.09%, while CPRX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CBT Cabot Corporation | 2.09% | 2.69% | 1.85% | 1.88% | 2.21% | 2.53% | 3.12% | 2.90% | 3.04% | 2.02% | 2.22% | 2.15% |
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
CBT vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Cabot Corporation and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CBT vs. CPRX - Profitability Comparison
CBT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cabot Corporation reported a gross profit of 211.00M and revenue of 849.00M. Therefore, the gross margin over that period was 24.9%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
CBT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cabot Corporation reported an operating income of 129.00M and revenue of 849.00M, resulting in an operating margin of 15.2%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
CBT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cabot Corporation reported a net income of 73.00M and revenue of 849.00M, resulting in a net margin of 8.6%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
CBT and CPRX have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CBT has higher volatility (11.97%) compared to CPRX (6.81%). In terms of maximum drawdown, CBT dropped -82.87% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (0.76 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CBT and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer